JOURNAL DESCRIPTION
The Medical Radiology and Radiation Safety journal ISSN 1024-6177 was founded in January 1956 (before December 30, 1993 it was entitled Medical Radiology, ISSN 0025-8334). In 2018, the journal received Online ISSN: 2618-9615 and was registered as an electronic online publication in Roskomnadzor on March 29, 2018. It publishes original research articles which cover questions of radiobiology, radiation medicine, radiation safety, radiation therapy, nuclear medicine and scientific reviews. In general the journal has more than 30 headings and it is of interest for specialists working in thefields of medicine¸ radiation biology, epidemiology, medical physics and technology. Since July 01, 2008 the journal has been published by State Research Center - Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency. The founder from 1956 to the present time is the Ministry of Health of the Russian Federation, and from 2008 to the present time is the Federal Medical Biological Agency.
Members of the editorial board are scientists specializing in the field of radiation biology and medicine, radiation protection, radiation epidemiology, radiation oncology, radiation diagnostics and therapy, nuclear medicine and medical physics. The editorial board consists of academicians (members of the Russian Academy of Science (RAS)), the full member of Academy of Medical Sciences of the Republic of Armenia, corresponding members of the RAS, Doctors of Medicine, professor, candidates and doctors of biological, physical mathematics and engineering sciences. The editorial board is constantly replenished by experts who work in the CIS and foreign countries.
Six issues of the journal are published per year, the volume is 13.5 conventional printed sheets, 88 printer’s sheets, 1.000 copies. The journal has an identical full-text electronic version, which, simultaneously with the printed version and color drawings, is posted on the sites of the Scientific Electronic Library (SEL) and the journal's website. The journal is distributed through the Rospechat Agency under the contract № 7407 of June 16, 2006, through individual buyers and commercial structures. The publication of articles is free.
The journal is included in the List of Russian Reviewed Scientific Journals of the Higher Attestation Commission. Since 2008 the journal has been available on the Internet and indexed in the RISC database which is placed on Web of Science. Since February 2nd, 2018, the journal "Medical Radiology and Radiation Safety" has been indexed in the SCOPUS abstract and citation database.
Brief electronic versions of the Journal have been publicly available since 2005 on the website of the Medical Radiology and Radiation Safety Journal: http://www.medradiol.ru. Since 2011, all issues of the journal as a whole are publicly available, and since 2016 - full-text versions of scientific articles. Since 2005, subscribers can purchase full versions of other articles of any issue only through the National Electronic Library. The editor of the Medical Radiology and Radiation Safety Journal in accordance with the National Electronic Library agreement has been providing the Library with all its production since 2005 until now.
The main working language of the journal is Russian, an additional language is English, which is used to write titles of articles, information about authors, annotations, key words, a list of literature.
Since 2017 the journal Medical Radiology and Radiation Safety has switched to digital identification of publications, assigning to each article the identifier of the digital object (DOI), which greatly accelerated the search for the location of the article on the Internet. In future it is planned to publish the English-language version of the journal Medical Radiology and Radiation Safety for its development. In order to obtain information about the publication activity of the journal in March 2015, a counter of readers' references to the materials posted on the site from 2005 to the present which is placed on the journal's website. During 2015 - 2016 years on average there were no more than 100-170 handlings per day. Publication of a number of articles, as well as electronic versions of profile monographs and collections in the public domain, dramatically increased the number of handlings to the journal's website to 500 - 800 per day, and the total number of visits to the site at the end of 2017 was more than 230.000.
The two-year impact factor of RISC, according to data for 2017, was 0.439, taking into account citation from all sources - 0.570, and the five-year impact factor of RISC - 0.352.
Medical Radiology and Radiation Safety. 2013. Vol. 58. No. 3. P. 34–38
RADIATION THERAPY
N.V. Belozor, T.V. Segeda, V.P. Starenkiy, N.A. Mitryaeva
Sfingomyelinasa for Monitoring of Chemoradioterapy Effectiveness in Cancer Treatment (Clinical and Experimental Investigation)
S.P. Grigoriev Medical Radiology Institute, National Academy of Medical Science of Ukraine, Kharkiv, Ukraine, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
Abstract
Purpose: To substantiate experimentally and investigate the possibility to use Zn2+-dependent acid sphingomyelinase (ASMase) in monitoring of efficacy of treatment for non-small-cell lung cancer (NSCLC).
Material and methods: The results of radiation therapy (RT) with two modes of accelerated fractionation and radiosensitizing with Etoposide in 45 patient with inoperable IIIA-IIIB NSCLC against a background of determining blood serum ASMase activity in the course of the treatment. ASMase activity, ceramide (CM) amount and sphingomyelin were investigated in the blood serum of rats with transplanted Guerin’s carcinoma at combined action of high-energy photon (HEP) radiation and Etoposide. The irradiation was delivered in two fractions up to 10 Gy with linear accelerator Clinac 600 Ϯ
Results: It was determined that blood serum ASMase activity in patients with NSCLC after chemoradiation treatment increased significantly in 2.9 times and was accompanied by the tumor regression (>50 %) in 73.3 % of cases. It was shown that increased activity of ASNase in 1.9 times, 4.7 time increase of and 2.5-time reduction of SPM were observed in the blood serum of the rat’s carriers of the tumor at combined action of HEP radiation and Etoposide.
Conclusion: ASMase activity level in the course of chemoradiation therapy against a background of determining the tumor regression can be used for monitoring of efficacy of chemoradiation treatment for NSCLC. This was substantiated by the findings of clinical investigations which allowed to suggest that a mechanism associated with ASMase activation is involved in induction of accumulation of pro-apoptotic lipid CM at combined action of irradiation and Etoposide. Therefore, the possibility to use determining ASMase activity as a serous marker of apoptosis ceramide pathway to assess the efficacy of chemoradiation therapy is obvious.
Key words: nonsmall lung cancer, chemoradiotherapy, Zn2+-dependent sphingomyelinase, ceramide, apoptosis